The Quiet Revolution: How a New Partnership Aims to Reinvent Your Visit

SAN DIEGO, CA – June 05, 2026 – In a move poised to reshape the landscape of routine medical care, diagnostic innovator General Fluidics and development powerhouse Invetech have announced a strategic collaboration. Their shared goal is to dismantle the decades-old model of centralized lab testing, bringing fast, high-quality blood diagnostics directly to the point of care. This partnership isn't just about new technology; it's about reimagining a future where critical health information is available in minutes, not days, transforming everything from rural clinics to urban urgent care centers.

The alliance aims to accelerate the deployment of General Fluidics' Axess platform, a compact system designed to function as a "lab-on-a-benchtop." For patients, this could mean the end of anxious waits for test results and multiple trips to the doctor. For clinicians, it promises the power of immediate data to make faster, more informed decisions.

"This was a critical decision for us," said Rob Granier, CEO of General Fluidics. "We needed a partner who had seen the hard problems before, who could move fast, be transparent, and help us scale with confidence. Invetech stood out not just for technical depth, but for how they show up as a true partner."

This sentiment of a perfectly timed union was echoed by Invetech's leadership. "The market is ready, the technology is mature, and decentralised testing is now the expectation," noted Andreas Knaack, CEO of Invetech. "Together, we're building a platform designed to scale and to make a real difference in healthcare."

A Paradigm Shift in Healthcare Delivery

The collaboration between General Fluidics and Invetech arrives at a pivotal moment for the healthcare industry. The point-of-care (PoC) diagnostics market is not just growing; it's exploding. Market analysts project the sector, valued at over $43 billion in 2024, to more than double to nearly $88 billion by 2032. This surge is fueled by a convergence of powerful forces: an aging population with a rising prevalence of chronic diseases, a growing demand for consumer-centric healthcare, and significant technological leaps.

For years, the standard has been a hub-and-spoke model where blood samples are collected at clinics, sent to large, centralized laboratories, and processed in batches. While efficient for high volumes, this system introduces significant delays that can impact patient outcomes. The decentralization movement seeks to upend this by equipping providers with tools that deliver immediate, actionable results. This is particularly crucial for managing conditions like diabetes and cardiovascular disease, and for the rapid identification of infectious diseases where time is of the essence.

The technology enabling this shift, particularly in microfluidics and biosensor innovation, has matured significantly. These advancements allow for the miniaturization of complex analytical processes that once required rooms of equipment, fitting them into compact, user-friendly devices. The promise is to provide results with an accuracy that rivals traditional reference labs, a crucial factor for clinical adoption.

General Fluidics' Axess: Redefining the Blood Test

At the heart of this new partnership is the Axess platform from General Fluidics. Born from research at the prestigious Massachusetts General Hospital, the company was founded with a singular mission: to make diagnostics genuinely accessible. The Axess system is the manifestation of that goal—a seamlessly integrated benchtop device capable of running hundreds of different tests across hematology, clinical chemistry, and immunoassays from a single blood sample.

Instead of waiting hours or days, a clinician using the Axess platform can get a comprehensive diagnostic panel within minutes. This capability could fundamentally alter patient management. In a rural clinic, a doctor could diagnose and begin treatment for an infection in a single visit. In a busy emergency room, it could accelerate triage and decision-making for patients with chest pain or signs of sepsis. The potential to reduce follow-up appointments, streamline workflows, and improve the patient experience is immense.

This ambitious vision has attracted significant financial backing. General Fluidics has raised a total of $34.6 million, including a recent $22.6 million Series B funding round that closed in mid-2024. This level of investment from venture capital and even the U.S. Department of Health and Human Services signals strong confidence in both the technology and its potential to address a critical market need.

The Partner for the Path to Market

An innovative idea, however brilliant, is only as good as its execution. Bringing a complex medical device from a prototype to a regulated, mass-produced product is a notoriously difficult journey fraught with regulatory, engineering, and manufacturing pitfalls. This is where Invetech's role becomes critical. After a global search, General Fluidics selected the firm for its three decades of experience in turning complex concepts into commercial realities.

Invetech's track record is a testament to its expertise. The company has been instrumental in the development of dozens of FDA and CE-approved devices, including the award-winning TEG 6s point-of-care hemostasis analyzer, which provides rapid insights into a patient's blood clotting ability. Their approach is defined by what they call an "end-to-end capability," integrating multidisciplinary teams from the project's inception. This "manufacturing mindset" ensures that from day one, the product is being designed not just to work, but to be built reliably, cost-effectively, and at scale.

This integrated process includes a rigorous "risk discipline," a systematic approach to identifying and mitigating potential failures in design, manufacturing, and regulatory compliance. With ISO-certified facilities and deep experience navigating the FDA's complex approval pathways, Invetech provides the structured framework necessary to transform General Fluidics' innovative platform into a market-ready, regulated product. As one MedTech executive who previously worked with the firm noted, "They don't just help you design a product; they help you build it for manufacturing, so you can scale with confidence."

The Future of Diagnostics: Opportunity and Obstacles

The push toward decentralization promises a more equitable and efficient healthcare system. The ability to perform high-quality tests in community clinics could dramatically bridge the health access gap between urban and rural populations, reducing the burden of travel and time off work for patients in underserved areas. Rapid diagnostics can lead to more targeted treatments, reduce the overuse of antibiotics, and lower overall healthcare costs by preventing hospitalizations and shortening stays.

However, this future is not without its challenges. Widespread adoption of PoC testing requires robust systems for quality assurance to ensure results are consistently accurate, regardless of where the test is performed. Healthcare systems will need to invest in comprehensive training for non-laboratory staff who will be operating these devices. Furthermore, data management is a critical hurdle; the vast amounts of data generated by thousands of decentralized devices must be securely and seamlessly integrated into electronic health records to provide a complete picture of a patient's health and avoid information silos.

The collaboration between General Fluidics and Invetech is a powerful signal that the industry is ready to tackle these challenges head-on. By combining a visionary diagnostic platform with proven scale-up expertise, this partnership is not merely an announcement of a new product, but a foundational step toward building the infrastructure for a new era of patient-centered care. The journey from innovation to impact is long, but with this alliance, the path to bringing the lab to the patient just became significantly shorter.